๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for HER2-Gastric/Gastroesophageal Junction Cancer

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer NCT05671822Phase 21 site๐Ÿ“ Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. ยท Tests: SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine, SHR-A1811, SHR-1316, and capeโ€ฆ A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles๐Ÿ“ Whittier Daiichi Sankyo ยท Tests: Ifinatamab deruxtecan A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer. NCT06902545n/a15 sites๐Ÿ“ Goyang-si๐Ÿ“ Suwon๐Ÿ“ Suwon Astellas Pharma Korea, Inc. ยท Tests: zolbetuximab First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373Phase 220 sites๐Ÿ“ Zhengzhou๐Ÿ“ Binzhou๐Ÿ“ Dongying Qilu Hospital of Shandong University ยท Tests: Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin A Phase โ…ข Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer NCT06532006Phase 3208 sites๐Ÿ“ Anaheim๐Ÿ“ Los Alamitos๐Ÿ“ Greeley Shanghai Henlius Biotech ยท Tests: HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients NCT06650332Phase 1, Phase 21 site๐Ÿ“ Hangzhou Zhejiang Cancer Hospital ยท Tests: cadonilimab, Trastuzumab, XELOX, Disitamab Vedotin, mFOLFOX6 Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer NCT07551362Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DT-CAR-NK, Fludarabine, Cyclophosphamide A Phase โ…ข Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875Phase 3304 sites๐Ÿ“ Anchorage๐Ÿ“ Phoenix๐Ÿ“ Duarte AstraZeneca ยท Tests: Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma NCT05677490Phase 3798 sites๐Ÿ“ Birmingham๐Ÿ“ Anchorage๐Ÿ“ Anchorage Alliance for Clinical Trials in Oncology ยท Tests: Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan, Nivolumab A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07315750Phase 31 site๐Ÿ“ Beijing RemeGen Co., Ltd. ยท Tests: Disitamab Vedotin, Tislelizumab, CAPOX (oxaliplatin/capecitabine), Trastuzumab, Pembrolizumab A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer NCT06901531Phase 3252 sites๐Ÿ“ Birmingham๐Ÿ“ Bakersfield๐Ÿ“ Cerritos Astellas Pharma Global Development, Inc. ยท Tests: zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent) SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen NCT06123494Phase 31 site๐Ÿ“ Shanghai Jiangsu HengRui Medicine Co., Ltd. ยท Tests: SHR-A1811, Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients NCT06277024NA1 site๐Ÿ“ Fuzhou Fujian Medical University ยท Tests: Combination of Cardonizumab with Lenvatinib and SOX regimen Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers NCT07464470n/a1 site๐Ÿ“ Moscow Blokhin's Russian Cancer Research Center ยท Tests: HER2 Testing, MSI Testing, PD-L1 Testing, CLDN18.2 Testing A Phase 2 Clinical Study of ABSK061 and ABSK043 NCT06632262Phase 221 sites๐Ÿ“ Guiyang๐Ÿ“ Guiyang๐Ÿ“ Shijiazhuang Abbisko Therapeutics Co, Ltd ยท Tests: ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma NCT05894824Phase 1, Phase 21 site๐Ÿ“ Seoul Yonsei University ยท Tests: T-Dxd(Trastuzmab deruxtecan), Ramucirumab Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma NCT07700979Phase 325 sites๐Ÿ“ Phoenix๐Ÿ“ Los Angeles๐Ÿ“ Denver Akeso ยท Tests: Cadonilimab, CAPOX regimen, Nivolumab, Placebo Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors NCT06750185Phase 1, Phase 211 sites๐Ÿ“ Louisville๐Ÿ“ Grand Rapids๐Ÿ“ Huntersville BioNTech SE ยท Tests: BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5 A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632Phase 1158 sites๐Ÿ“ Anchorage๐Ÿ“ Fayetteville๐Ÿ“ Rogers Seagen, a wholly owned subsidiary of Pfizer ยท Tests: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer NCT06158919NA1 site๐Ÿ“ Shanghai Fudan University ยท Tests: Fruquintinibใ€Nivolumabใ€Sintilimabใ€Oxaliplatinใ€Teysunoใ€Capecitabine Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors NCT07660055Phase 15 sites๐Ÿ“ Omaha๐Ÿ“ Darlinghurst๐Ÿ“ Montreal Novartis Pharmaceuticals ยท Tests: [68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187Phase 110 sites๐Ÿ“ Denver๐Ÿ“ Orlando๐Ÿ“ Sarasota Dren Bio ยท Tests: DR-0202 Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281Phase 3314 sites๐Ÿ“ Birmingham๐Ÿ“ Mobile๐Ÿ“ Anchorage AstraZeneca ยท Tests: Sonesitatug vedotin, Rilvegostomig, Nivolumab, Capecitabine, 5-Fluorouracil A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer NCT07673887Phase 38 sites๐Ÿ“ Saint Louis Park๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Astellas Pharma Global Development, Inc. ยท Tests: ASP2138, Pembrolizumab, Oxaliplatin, Capecitabine, Folinic acid Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors NCT06293898Phase 126 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Los Angeles SystImmune Inc. ยท Tests: BL-M07D1 At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860Phase 22 sites๐Ÿ“ Jacksonville๐Ÿ“ Grand Forks Mayo Clinic ยท Tests: Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment, Questionnaire Administration Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT06731478Phase 3250 sites๐Ÿ“ New Haven๐Ÿ“ Skokie๐Ÿ“ Kansas City Daiichi Sankyo ยท Tests: Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab, Chemotherapy A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG NCT06774222Phase 21 site๐Ÿ“ Zhengzhou Henan Cancer Hospital ยท Tests: Fruquintinib Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread NCT06324357Phase 1, Phase 2104 sites๐Ÿ“ Cerritos๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles Boehringer Ingelheim ยท Tests: Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. NCT06177041Phase 31 site๐Ÿ“ Beijing FutureGen Biopharmaceutical (Beijing) Co., Ltd ยท Tests: M108 monoclonal antibody, Placebo, Oxaliplatin, Capecitabine
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy